Starting etoposide early or later in severe hemophagocytic lymphohistiocytosis in intensive care
Compares early versus delayed etoposide in adults with severe hemophagocytic lymphohistiocytosis in intensive care.
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France and Guadeloupe24 sites in 2 countriesChoose a country to see its sites
- Trial code
- Registry title
- Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 176 people, planned
- Started
- Apr 2026
- Expected to end
- Feb 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Etoposide (Early strategy)
- Etoposide (Delayed strategy)
- Record updated
- 23 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in intensive care with a first episode of severe hemophagocytic lymphohistiocytosis (HLH), an immune overreaction, causing organ failure. It compares giving etoposide early versus later.
- Age
- 18 years and older.
- Sex
- All sexes can join.
- Disease stage
- Confirmed first episode of HLH, admitted to intensive care, with failure of at least one organ: circulation, breathing, kidneys (stage 2 or higher by KDIGO) or brain (GCS ≤ 13).
- Earlier treatment
- Cannot join if treated with etoposide before intensive care admission, after CAR-T cell therapy, or if HLH started within 15 days after chemotherapy for cancer or a blood cancer.
- Biomarker or test result
- HScore of 169 or more.
Main reasons for not taking part
- Dying patients with shock needing noradrenaline > 2.5 µg/kg/min
- Etoposide cannot be given within 12 hours
- Allergy to etoposide or dexamethasone, or unable to take dexamethasone
- Pregnant or breastfeeding women, or pregnancy not ruled out
- Recent live attenuated vaccine, or taking part in another interventional study
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Adult patient
- Confirmed diagnosis of HLH:; Hscore ≥ 169; Diagnosis of HLH established by the multidisciplinary team caring for the patient(A 24/7 hotline will be available in case of diagnostic uncertainty: this will be the direct line to the on-call intensivist at Avicenne Hospital, who can contact the coordinating investigator as needed)
- First episode of HLH
- Admission to intensive care unit
- Presence of one or more organ failures:; Circulatory: mBP < 65 mmHg with lactate > 2 mmol/L, or treatment with catecholamines; Respiratory: oxygen therapy > 6 L/min or need for non-invasive ventilation, high-flow nasal cannula oxygen therapy, or invasive mechanical ventilation; Renal: stage 2 or higher according to KDIGO criteria, defined by a creatinine increase ≥ 2 times baseline, or urine output < 0.5 mL/kg/h for ≥ 12 hours, or initiation of renal replacement therapy; Neurological: GCS ≤ 13
Who cannot take part
- Patient treated with etoposide prior to admission to the intensive care unit
- Recent vaccination with a live attenuated vaccine
- Moribund patient with refractory distributive shock: multi-organ failure requiring noradrenaline > 2.5 µg/kg/min and imminent risk of death
- Hypersensitivity to etoposide or any of its excipients
- Hypersensitivity or contraindication to dexamethasone or any of its excipients, as described in the package insert for the dexamethasone specialty used in the trial and in the protocol
- Patient with a history of CAR-T cell therapy
- Patient developing HLH within 15 days following chemotherapy for cancer or hematologic malignancy
- Pregnant women (positive βhCG), women for whom pregnancy has not been excluded (βhCG not performed in women of childbearing age), or lactating women
- Inability to administer etoposide within 12 hours
- Patient not covered by social security
- Patient under legal guardianship, tutelage, or curatorship
- Minor patient
- Participation in another interventional research study
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Hemophagocytic lymphohistiocytosis (HLH) is an immune-mediated disorder characterized by hyperactivation of the immune system, leading to a cytokine storm responsible for organ failures. Consequently, patients with HLH often require intensive care management, where their short-term prognosis is compromised (1-month mortality: 30 to 40%).
Read full original descriptionShow less
Therapeutic management is urgent and consists in treating associated pathologies and employing immunomodulatory therapy. Currently, there are no clear and consistent recommendations for guiding immunomodulatory treatment in HLH due to the lack of high-level evidence studies. Experts recommend corticosteroid therapy for mild forms, whereas etoposide is proposed for severe cases, especially those with organ failures. However, in clinical practice, its use in patients with multi-organ failure is not systematic due to concerns about potential severe side effects and uncertainty regarding the contribution of severe sepsis to the clinical and biological presentation. Consequently, initiation of etoposide is sometimes delayed.
Our hypothesis is that early treatment of severe HLH associated with organ failure using etoposide could reduce organ failures associated with this syndrome. Therefore, we aim to compare two strategies for initiating etoposide in severe HLH in intensive care: an early strategy where etoposide is prescribed at the onset of HLH-related organ failure, and a delayed strategy where etoposide is prescribed only if there is unfavorable progression (or lack of improvement) after treating associated pathologies, associated with corticosteroid therapy.
The 2 groups in the trial
- Early strategyTreatment being tested
Etoposide treatment will be administered within 12 hours of inclusion.
Treatment: Etoposide (Early strategy)
- Delayed strategyExisting treatment, for comparison
The need for etoposide treatment will be reassessed after 48 hours of management. If organ failure worsens or fails to improve (modified SOFA increase ≥1 point or stable), etoposide will be administered within 12 hours of reassessment. In cases of rapidly deteriorating clinical status with short-term life-threatening prognosis (defined as an increase of 6 or more points in modified SOFA score), patients may receive rescue treatment (before 48 hours) with etoposide at the discretion of the medical team managing the patient; in such cases, the Day-2 infusion will not be administered.
Treatment: Etoposide (Delayed strategy)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis in Intensive Care: a Randomized Trial
- Plain-language title
- Starting etoposide early or later in severe hemophagocytic lymphohistiocytosis in intensive careGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 23 April 2026